Principal-led CMC and regulatory advice for complex biologics, including cell and gene therapies.
From discovery to first-in-human (FIH) and beyond, we help founders, institutes and investors understand the development path early. We then guide programs through FIH readiness, CTN, INTERACT, pre-IND, IND and BLA.
“Penny reviewed laboratory data from one of our discovery-stage programs and delivered a clear CMC and regulatory pathway. Her report provided the clarity required to assess investment potential and plan subsequent steps. Penny combines deep technical expertise with a practical, commercially aware approach. Her work was rigorous, pragmatic and I would highly recommend her.”
— Dr Carli Roulston, Head of Commercial Ventures, Burnet Institute